What percentage of Magnetic Resonance Imaging (MRI) studies require a high field strength in addition?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Percentage of MRI SWOOP Studies Requiring High Field Imaging

Based on the available evidence, there is no specific percentage of low-field MRI SWOOP studies that require additional high-field imaging, but all MRI scans for multiple sclerosis should be performed at a minimum field strength of 1.5T for optimal diagnostic accuracy and monitoring.

Field Strength Requirements for MS Imaging

Minimum Field Strength Recommendations

  • Guidelines consistently recommend a minimum field strength of 1.5T for MS diagnosis and monitoring 1
  • Lower field strengths (e.g., 0.15T) require thicker slices (10mm) which results in poor lesion detection, with up to 40% of new lesions disappearing on follow-up compared to only 6% at higher field strengths 1
  • The American College of Radiology also recommends a minimum field strength of 1.5T for diagnostic quality MRI images 2

Benefits of Higher Field Strengths (3.0T and above)

  • 3.0T scanners allow detection of significantly more lesions in CIS patients, with improved recognition of lesions in cortical, infratentorial, and periventricular regions 1
  • Ultra-high-field MRI (7.0T) allows detection of significantly more lesions and better definition of lesion morphology and vascular relationships 1
  • Higher field strengths improve visualization of:
    • Central veins within MS lesions
    • Perivenular lesion location
    • Rim of hypointensity on T2*-weighted images 1

Impact on Diagnosis and Monitoring

Diagnostic Impact

  • Despite higher lesion detection rates at 3.0T, one study showed that only one additional patient was diagnosed with dissemination in space at high field compared to 1.5T 3
  • The use of high-field or ultra-high-field scanners is not likely to result in an earlier diagnosis of MS 1
  • During follow-up, an earlier diagnosis of definite MS could not be accomplished using high-field MRI, neither according to the International Panel nor to the Swanton criteria 3

Monitoring Considerations

  • Follow-up MRI should be conducted at least once every year in patients with MS, but patients at risk of serious treatment-related adverse events may need more frequent monitoring (every 3–4 months) 1
  • For follow-up scans, fewer sequences are necessary than for diagnosis, but the field strength should remain consistent 1
  • Serial examination of individual patients should be undertaken on the same scanner to minimize variation in image quality 1

Technical Specifications

  • For 2D sequences, slice thickness should be no more than 3mm with an in-plane spatial resolution of 1×1mm 1
  • Voxels in 3D sequences should be 1mm³ 1
  • Axial orientation is recommended as the most widely accepted approach 1
  • Gadolinium enhancement is valuable for:
    • Detecting inflammatory activity in older lesions
    • Visualizing cortical and subcortical lesions not visible on unenhanced T2-weighted MRI
    • Increasing conspicuousness of small new lesions 1

Conclusion

While higher field strengths (3.0T and above) offer improved lesion detection and characterization, there is no specific percentage of SWOOP studies that require additional high-field imaging. However, the evidence strongly indicates that all MS imaging should be performed at a minimum field strength of 1.5T to ensure adequate diagnostic accuracy and monitoring capability.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

MRI Analysis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.